Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
Anixa completed dosing of the fifth cohort in its Phase 1 trial of its FSHR-targeted CAR-T therapy for recurrent ovarian cancer, at the highest dose evaluated to date (1x10^7 CAR-positive cells/kg). No dose-limiting toxicities have been observed across any cohort, and four patients have surpassed one year of survival post-treatment (approximately 28, 21, 17, and 17 months), with the first fifth-cohort patient showing stable disease at 90 days. The sixth cohort, escalating to 1x10^8 cells/kg, is expected to begin after a routine 30-day safety verification.
Key figures
- Drug Name
- liraltagene autoleucel (lira-cel), FSHR-targeted CAR-T
- Phase Of Trial
- Phase 1
- Cohort dose
- 1x10^7 CAR-positive cells/kg following lymphodepletion
- Next cohort dose
- 1x10^8 CAR-positive cells/kg
- Longest survival months
- 28
- Patients surviving over one year
- 4
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.